AVAC’s report for HIV Vaccine Awareness Day on the state of the HIV vaccine research and development field, including key priorities for advancing research and sustaining support.
Advocacy in Uncertain Times: A call to action
Financing the Search: Then and now
Funding for vaccines research in 1997 and 2016, segmented by government and other sector spending.
Number of Vaccines Trials: Then and now
A snapshot of the number of vaccine trials conducted globally between 1997 and 2017.
HIV-Specific Neutralizing Antibodies: A guide to targets and candidates
A detailed graphic describing the status of pre-clinical and clinical work around relevant bNAbs today.
Where Does Oral PrEP Fit in to Vaccine and AMP Trials?
A global map showing current efficacy trial countries and their status of PrEP implementation.
Vaccines and Antibodies on Efficacy Pathways
A timeline of current efficacy programs for vaccines and antibodies, highlighting the P5 program testing pox-protein candidates, the Janssen program testing mosaic-based candidates, and the AMP studies testing the antibody VRC01.
Px Wire April-June 2017, Vol. 10, No. 2
This issue of Px Wire, AVAC’s quarterly update on HIV prevention research, offers an advocate’s guide to some new types of biomedical prevention trial designs. You’ll find a summary of long-acting PrEP trials, a lexicon of key terms for the “post-placebo era”, and a handy illustration for looking smart while you explain “double-dummy double-blind”.
Regulatory Status of TDF/FTC for PrEP
A global snapshot of the regulatory status of oral PrEP by country. JPEG and PPT versions available here.
AIDS Vaccine Science for Busy Advocates: Antibody Research
A primer on antibodies and their role in HIV prevention research. Read on for a glossary of relevant terms and to learn how broadly neutralizing antibodies may be important to the development of a vaccine.
What Is Up With DMPA And “Grades” For Family Planning?
AVAC’s sheet on the hormonal contraceptive known as Depo-Provera (DMPA) and the WHO grading system for contraceptives explains key issues in plain language. Research findings have raised questions about the safety and effectiveness of DMPA for women who face a high risk of HIV. WHO evaluates the safety and efficacy of contraceptive methods.